Awareness, attitudes and acceptability of the HPV vaccine among female university students in Morocco.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
28
04
2021
accepted:
14
03
2022
entrez:
8
4
2022
pubmed:
9
4
2022
medline:
15
4
2022
Statut:
epublish
Résumé
In Morocco, cervical cancer is the second most common cancer affecting women behind breast cancer. The Human PapillomaVirus (HPV) vaccine has been available in Morocco since 2008 but its introduction in the national immunization program is still under discussion. There is limited data regarding acceptability and predictors of HPV vaccine acceptability among Moroccan young women. This study aimed to evaluate the awareness of female university students of HPV and the vaccine and to identify predictors of HPV vaccine acceptability. We conducted a structured interviewer-administered questionnaire with 1087 participants in six Moroccan universities between May 2019 and June 2020. The awareness of HPV infection was 14.7% and of HPV vaccine was 7.8%. The rate of immunization coverage against HPV was less than 1%. Over 67% of participants were willing to receive the HPV vaccine. Awareness of cervical cancer (p-Value = 0.04) and the HPV vaccine (p-Value = 0.01), and acceptability of Pap smear test (p-Value <0.01) were significant predictors of HPV vaccine acceptability. This study revealed an insufficient amounts of awareness of HPV and of HPV vaccine uptake in a sample of Moroccan university young women. This lack of awareness needs intervention, and it is important to develop an awareness program for young female population either within or outside universities in order to promote vaccination uptake and ultimately lower the cervical cancer rate in Morocco.
Sections du résumé
BACKGROUND
In Morocco, cervical cancer is the second most common cancer affecting women behind breast cancer. The Human PapillomaVirus (HPV) vaccine has been available in Morocco since 2008 but its introduction in the national immunization program is still under discussion. There is limited data regarding acceptability and predictors of HPV vaccine acceptability among Moroccan young women. This study aimed to evaluate the awareness of female university students of HPV and the vaccine and to identify predictors of HPV vaccine acceptability.
METHODS
We conducted a structured interviewer-administered questionnaire with 1087 participants in six Moroccan universities between May 2019 and June 2020.
RESULTS
The awareness of HPV infection was 14.7% and of HPV vaccine was 7.8%. The rate of immunization coverage against HPV was less than 1%. Over 67% of participants were willing to receive the HPV vaccine. Awareness of cervical cancer (p-Value = 0.04) and the HPV vaccine (p-Value = 0.01), and acceptability of Pap smear test (p-Value <0.01) were significant predictors of HPV vaccine acceptability.
CONCLUSIONS
This study revealed an insufficient amounts of awareness of HPV and of HPV vaccine uptake in a sample of Moroccan university young women. This lack of awareness needs intervention, and it is important to develop an awareness program for young female population either within or outside universities in order to promote vaccination uptake and ultimately lower the cervical cancer rate in Morocco.
Identifiants
pubmed: 35395019
doi: 10.1371/journal.pone.0266081
pii: PONE-D-21-14104
pmc: PMC8993020
doi:
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0266081Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Family Community Med. 2016 Sep-Dec;23(3):145-50
pubmed: 27625580
JAMA. 2007 Feb 28;297(8):813-9
pubmed: 17327523
Cancer Control. 2021 Jan-Dec;28:10732748211032899
pubmed: 34634207
Vaccine. 2012 Nov 20;30 Suppl 5:F139-48
pubmed: 23199957
Hum Vaccin Immunother. 2021 Aug 3;17(8):2736-2747
pubmed: 33787459
Front Oncol. 2015 Jun 24;5:141
pubmed: 26157706
Int J Cancer. 2013 Feb 15;132(4):932-43
pubmed: 22689326
J Med Virol. 2021 Dec 7;:
pubmed: 34877678
Lancet Glob Health. 2020 Feb;8(2):e191-e203
pubmed: 31812369
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Pathol. 1999 Sep;189(1):12-9
pubmed: 10451482
Nurs Health Sci. 2017 Dec;19(4):414-426
pubmed: 29058371
Vaccine. 2019 Sep 24;37(41):6030-6038
pubmed: 31473002
Eur J Cancer. 2013 Apr;49(6):1264-72
pubmed: 23290788
Sci Rep. 2018 Feb 26;8(1):3640
pubmed: 29483541
J Prim Care Community Health. 2017 Oct;8(4):349-362
pubmed: 29161946
Eur J Obstet Gynecol Reprod Biol. 2010 Jan;148(1):90-5
pubmed: 19910102
Infect Dis (Auckl). 2019 Jan 28;12:1178633718825077
pubmed: 30728723
Vaccine. 2018 Aug 6;36(32 Pt A):4761-4767
pubmed: 29580641
J Pediatr Adolesc Gynecol. 2016 Jun;29(3):292-8
pubmed: 26612116
Vaccine. 2014 Jan 9;32(3):409-16
pubmed: 24188754
Women Health. 2015;55(5):566-79
pubmed: 25833319